Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Residual disease assessed with whole body MRI per MY-RADS protocol linked to shorter PFS (median 24 vs. 42 months) and OS (median 47 months vs. NE) in newly diagnosed or at first relapse patients undergoing first ASCT.”
Title: Whole body MRI by MY-RADS for imaging response assessment in multiple myeloma
Authors: Christina Messiou, Nuria Porta, Dow-Mu Koh, Angela Riddell, Katherine Downey, James Croft, Leonora Conneely, Georgina Hopkinson, Alina Dragan, Tommy Brown, Simon Stern, Betty Cheung, Charalampia Kyriakou, Pawel Kaczmarek, Kevin Boyd, Charlotte Pawlyn, Jessica Winfield, Martin F. Kaiser
You can read the Full Article in Blood Cancer Journal.
You can find more posts featuring Robert Orlowski in OncoDaily.
